Suzhou Ribo Life Science Co., Ltd, a specialist in small interfering RNA (siRNA) drugs based in China, has entered into a licensing agreement with Qilu Pharmaceutical, granting the company clinical development, manufacturing, and commercialization rights to its PCSK9 siRNA drug RBD7022 in Greater China, which includes mainland China, Hong Kong, and Macau.
According to the agreement, Qilu Pharmaceutical will pay Ribo Life Science an upfront and milestone payment of more than RMB 700 million (USD 98 million), in addition to double-digit royalties on future sales.
RBD7022, a GalNAc-conjugated siRNA drug developed by Ribo Life Science, utilizes the company’s proprietary RIBO GalSTAR liver-targeted delivery technology. The drug is in development for the treatment of hyperlipidemia by inhibiting the expression of PCSK9 protein, reducing lysosomal degradation of the low-density lipoprotein receptor (LDL-R), and lowering blood LDL-C levels. Currently in Phase I, RBD7022 has demonstrated good safety and tolerability, significant lipid-lowering effects, and the potential for extended dosing intervals, which could greatly enhance patient compliance.- Flcube.com
